Transcept gains cash and public listing through Novacea merger
This article was originally published in Scrip
Transcept Pharmaceuticals is to gain $84 million in cash and become a publicly listed company through a merger with Novacea. Transcept improves existing drugs or develops new indications for existing prescription sleep medicine and psychiatry drugs and its lead agent Intermezzo (zolpidem), for middle-of-the-night insomnia, has completed two Phase III trials.
You may also be interested in...
Laura Gonz�lez-Molero will be celebrating her first anniversary as President of Bayer HealthCare Pharmaceuticals, Latin America this month. With Bayer posting total sales of €1.05bnin Latin America in 2014, up 13% over 2013, Ms Gonz�lez-Molero should be pleased with a successful inaugural year. Resolute in her belief that innovation, "part of Bayer's DNA," will determine the company's long-term success in Latin America, rather than growth through acquisition, Ms Gonz�lez-Molero talks to Scrip about her personal ambitions for the company and the region.
A decade since its formation Anvisa, Brazil's medicines regulator, has shaken up the country's framework for ensuring drug quality. Yet the agency's approaches to drug pricing and registration have left some multinationals wanting, reports Sita Shah.
Elan is raising $1.5 billion in bonds to refinance its existing debt and for general corporate purposes, it says.